Retrospective Survey of Safety of Fourth Dose Pentacel® in Children
NCT ID: NCT00772369
Last Updated: 2014-02-14
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
3214 participants
OBSERVATIONAL
2003-09-30
2005-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Primary Objective:
To collect selected safety data at 6 months following the 4th dose of the Pentacel® series.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five Years
NCT00452621
Safety Profile Following Pentabio Vaccination in Indonesian Infants
NCT02093286
Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines
NCT01129362
A Phase IV Study to Assess the Safety of EupentaTM Inj
NCT04056728
Immunogenicity and Safety of Pentaxim in South African Infants
NCT00254969
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written Informed Consent and Telephone consent from the parent(s) or guardian(s).
* Able to comply with the survey procedures.
Exclusion Criteria
12 Months
24 Months
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi Pasteur, a Sanofi Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Sanofi Pasteur Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vancouver, British Columbia, Canada
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M5A08
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.